Terms: = Cervical cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
940 results:
1. Prevalence of high-risk human papillomavirus genotypes in outpatient Malian women living with HIV: a pilot study.
Traore B; Kassogue Y; Diakite B; Diarra F; Cisse K; Kassogue O; Diarra M; Coulibaly A; Coulibaly B; Diallo H; Diarra Z; Ly M; Maiga A; Sissoko SB; Sissoko AS; Traore CB; Kamate B; Teguete I; Bah S; Dolo G; Gursel DB; Holl J; Hou L; Maiga M
BMC Infect Dis; 2024 May; 24(1):513. PubMed ID: 38778266
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
Liu Y; Shi W; Mubarik S; Wang F
BMC Public Health; 2024 May; 24(1):1349. PubMed ID: 38764017
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Wu Y; Jiang P; Chen Z; Li W; Dong B; Zhang Y
BMC Cancer; 2024 May; 24(1):589. PubMed ID: 38745137
[TBL] [Abstract] [Full Text] [Related]
4. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
5. Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries.
Fackler MJ; Pleas M; Li Y; Soni A; Xing D; Cope L; Ali S; Van Le Q; Van Nguyen C; Pham HT; Duong LM; Vanden Berg E; Wadee R; Michelow P; Chen WC; Joffe M; Fjeldbo CS; Lyng H; Sukumar S
Clin Epigenetics; 2024 Apr; 16(1):56. PubMed ID: 38643219
[TBL] [Abstract] [Full Text] [Related]
6. Predicting treatment plan approval probability for high-dose-rate brachytherapy of cervical cancer using adversarial deep learning.
Gao Y; Gonzalez Y; Nwachukwu C; Albuquerque K; Jia X
Phys Med Biol; 2024 Apr; 69(9):. PubMed ID: 38537309
[No Abstract] [Full Text] [Related]
7. Artificial Intelligence-Based Radiotherapy Contouring and Planning to Improve Global Access to cancer Care.
Court LE; Aggarwal A; Jhingran A; Naidoo K; Netherton T; Olanrewaju A; Peterson C; Parkes J; Simonds H; Trauernicht C; Zhang L; Beadle BM;
JCO Glob Oncol; 2024 Mar; 10():e2300376. PubMed ID: 38484191
[TBL] [Abstract] [Full Text] [Related]
8. Should we use risk selection tests for HPV 16 and/or 18 positive cases: Comparison of p16/Ki67 and cytology.
Mazurec K; Trzeszcz M; Mazurec M; Streb J; Halon A; Jach R
J Med Virol; 2024 Mar; 96(3):e29500. PubMed ID: 38440951
[TBL] [Abstract] [Full Text] [Related]
9. Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.
Coutinho F; Gokhale M; Doran C; Monberg M; Yamada K; Chen L
Cancer Treat Res Commun; 2024; 39():100800. PubMed ID: 38430610
[TBL] [Abstract] [Full Text] [Related]
10. Assisted reproductive technology treatment failure and the detection of intrauterine HPV through spent embryo transfer media sample.
Bai M; Sun D; Shu J; Wei D; Yuan M; Yuan Z; Liu S; Kang M; Zhang Z; Chen X; Zheng W; Feng Y; Bao S; Zhang Z; Liao H
J Med Virol; 2024 Mar; 96(3):e29468. PubMed ID: 38415499
[TBL] [Abstract] [Full Text] [Related]
11. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line treatment in Recurrent or Metastatic cervical cancer (COMPASSION-13): A Phase 2 Study.
Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
[TBL] [Abstract] [Full Text] [Related]
12. Communicable and Non-communicable Diseases Diagnosis and treatment Service Availability at Primary Health Care Units During COVID-19 Outbreak in Ethiopia.
Gonete TZ; Asseffa NA; Gashu KD; Tilahun B; Angaw DA; Jisso M; Tamiso A; Alemayehu A; Fikre R; Abdisa B; Sime H; Yesuf EA; Umer A; Kebede M; Mohammed H; Yazie B; Gurmu KK; Endehabtu BF
Ethiop J Health Sci; 2023 Oct; 33(Spec Iss 2):95-104. PubMed ID: 38352666
[TBL] [Abstract] [Full Text] [Related]
13. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of clinical, immunological characteristics, damage, and survival in 300 Turkish systemic lupus erythematosus patients.
Tekeoglu S; Temiz Karadag D; Ozdemir Isik O; Yazici A; Cefle A
Lupus; 2024 Mar; 33(3):298-311. PubMed ID: 38258530
[TBL] [Abstract] [Full Text] [Related]
15. Relationship between Cervicovaginal Microecological Changes and HPV16/18 Infection and cervical cancer in Women of Childbearing Age.
Zhang Z; Yang Y; Zhang L; Wu Y; Jia P; Ma Q; Wang D
Ann Clin Lab Sci; 2023 Nov; 53(6):825-834. PubMed ID: 38182150
[TBL] [Abstract] [Full Text] [Related]
16. [Survival analysis of malignant tumors in cancer registration areas of Hubei province in China, 2013 to 2015].
Yao S; Xiong B; Tuo JY; Qin Y; Meng FD; Xia YF; Zhang M; Wei SZ
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):1051-1056. PubMed ID: 38110313
[No Abstract] [Full Text] [Related]
17. Endoscopic thyroidectomy via areola approach for stage T1 papillary thyroid carcinoma: feasibility, safety, and oncologic outcomes.
Huo J; Xu Y; Yu J; Guo Y; Hu X; Ou D; Qu R; Zhao L
Front Endocrinol (Lausanne); 2023; 14():1212490. PubMed ID: 38075056
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of the effectiveness and safety of photodynamic therapy in the treatment of precancerous diseases of the cervix (neoplasia) associated with the human papillomavirus: A systematic review.
Shanazarov N; Bariyeva G; Avdeyev A; Albayev R; Kisikova S; Zinchenko S; Galiev I
Photodiagnosis Photodyn Ther; 2024 Feb; 45():103925. PubMed ID: 38070631
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.
Li K; Chen J; Hu Y; Wang YZ; Shen Y; Chen G; Peng W; Fang Z; Xia B; Chen X; Song K; Wang Y; Zou D; Wang YC; Han Y; Feng X; Yuan J; Guo S; Meng X; Feng C; Chen Y; Yang J; Fan J; Wang J; Ai J; Ma D; Sun C
Lancet Oncol; 2024 Jan; 25(1):76-85. PubMed ID: 38048802
[TBL] [Abstract] [Full Text] [Related]
20. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A; Gladieff L; Martínez-García J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Fariñas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcón J; Follana P; Romero I; Lebreton C; Pérez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall LM;
Lancet; 2024 Jan; 403(10421):31-43. PubMed ID: 38048793
[TBL] [Abstract] [Full Text] [Related]
[Next]
